<VariationArchive VariationID="936" VariationName="NM_000404.4(GLB1):c.75+2dup" VariationType="Duplication" Accession="VCV000000936" Version="12" RecordType="classified" NumberOfSubmissions="9" NumberOfSubmitters="8" DateLastUpdated="2024-04-06" DateCreated="2013-04-04" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="15975" VariationID="936">
      <GeneList>
        <Gene Symbol="GLB1" FullName="galactosidase beta 1" GeneID="2720" HGNC_ID="HGNC:4298" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="32961108" stop="33097146" display_start="32961108" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33038099" stop="33138693" display_start="33038099" display_stop="33138693" Strand="-" />
          </Location>
          <OMIM>611458</OMIM>
        </Gene>
        <Gene Symbol="LOC129936434" FullName="ATAC-STARR-seq lymphoblastoid silent region 14182" GeneID="129936434" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33096734" stop="33097343" display_start="33096734" display_stop="33097343" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="TMPPE" FullName="transmembrane protein with metallophosphoesterase domain" GeneID="643853" HGNC_ID="HGNC:33865" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33090422" stop="33097146" display_start="33090422" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33131907" stop="33138292" display_start="33131907" display_stop="33138292" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000404.4(GLB1):c.75+2dup</Name>
      <CanonicalSPDI>NC_000003.12:33097008:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>3p22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33097008" stop="33097009" display_start="33097008" display_stop="33097009" variantLength="1" positionVCF="33097008" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33138500" stop="33138501" display_start="33138500" display_stop="33138501" variantLength="1" positionVCF="33138500" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
      </Location>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009005.1" sequenceAccession="NG_009005" sequenceVersion="1" change="g.5194dup">
            <Expression>NG_009005.1:g.5194dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.2" sequenceAccession="NM_000404" sequenceVersion="2" change="c.75+2dup">
            <Expression>NM_000404.2:c.75+2dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.33138501dup" Assembly="GRCh37">
            <Expression>NC_000003.11:g.33138501dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.33097009dup" Assembly="GRCh38">
            <Expression>NC_000003.12:g.33097009dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001039770.3" sequenceAccession="NM_001039770" sequenceVersion="3" change="c.-399dup" MANESelect="true">
            <Expression>NM_001039770.3:c.-399dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001136238.2" sequenceAccession="NM_001136238" sequenceVersion="2" change="c.-295dup">
            <Expression>NM_001136238.2:c.-295dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001393580.1" sequenceAccession="NM_001393580" sequenceVersion="1" change="c.75+2dup">
            <Expression>NM_001393580.1:c.75+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001135602.3" sequenceAccession="NM_001135602" sequenceVersion="3" change="c.75+2dup">
            <Expression>NM_001135602.3:c.75+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.75+2dup" MANESelect="true">
            <Expression>NM_000404.4:c.75+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317040.2" sequenceAccession="NM_001317040" sequenceVersion="2" change="c.75+2dup">
            <Expression>NM_001317040.2:c.75+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.2" sequenceAccession="NM_000404" sequenceVersion="2" change="c.75+2dupT">
            <Expression>NM_000404.2:c.75+2dupT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="587776525" DB="dbSNP" />
        <XRef ID="CA114651" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="611458.0014" DB="OMIM" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00003" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00015" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00020" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00021" Source="The Genome Aggregation Database (gnomAD)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000404.4(GLB1):c.75+2dup AND Infantile GM1 gangliosidosis" Accession="RCV000000985" Version="8">
        <ClassifiedConditionList TraitSetID="244">
          <ClassifiedCondition DB="MedGen" ID="C0268271">Infantile GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2020-06-11" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.75+2dup AND not provided" Accession="RCV000412989" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.75+2dup AND multiple conditions" Accession="RCV000796145" Version="5">
        <ClassifiedConditionList TraitSetID="10013">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.75+2dup AND Mucopolysaccharidosis, MPS-IV-B" Accession="RCV000781443" Version="1">
        <ClassifiedConditionList TraitSetID="247">
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-05-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.75+2dup AND GM1 gangliosidosis type 3" Accession="RCV001376158" Version="1">
        <ClassifiedConditionList TraitSetID="246">
          <ClassifiedCondition DB="MedGen" ID="C0268273">GM1 gangliosidosis type 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1994-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.75+2dup AND GM1 gangliosidosis type 2" Accession="RCV003338377" Version="2">
        <ClassifiedConditionList TraitSetID="245">
          <ClassifiedCondition DB="MedGen" ID="C0268272">GM1 gangliosidosis type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-19" NumberOfSubmissions="9" NumberOfSubmitters="8" DateCreated="2013-04-04" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17576681</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21497194</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29160035</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8198123</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8199591</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9536098</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="10013" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="244" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5204" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GM1 gangliosidosis type 1</ElementValue>
                <XRef ID="MONDO:0009260" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile GM1 gangliosidosis</ElementValue>
                <XRef ID="238026007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-gangliosidosis, type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, infantile form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6479" />
                <XRef ID="6479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79255" DB="Orphanet" />
              <XRef ID="C0268271" DB="MedGen" />
              <XRef ID="MONDO:0009260" DB="MONDO" />
              <XRef Type="MIM" ID="230500" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="245" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1390" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, juvenile type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Juvenile GM&gt;1&lt; gangliosidosis</ElementValue>
                <XRef ID="18756002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0022" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 2</ElementValue>
                <XRef ID="MONDO:0009261" DB="MONDO" />
                <XRef ID="79256" DB="Orphanet" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">GLB1-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10126" />
                <XRef ID="10126" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79256" DB="Orphanet" />
              <XRef ID="C0268272" DB="MedGen" />
              <XRef ID="MONDO:0009261" DB="MONDO" />
              <XRef Type="MIM" ID="230600" DB="OMIM" />
              <Comment DataSource="NCBI curation" Type="public">REVIEWED: Set the orphanet value to preferred to avoid the annotation for the subscript</Comment>
            </Trait>
          </TraitSet>
          <TraitSet ID="246" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1939" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta-galactosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult GM1 gangliosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type 3 (adult) GM1 gangliosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 3</ElementValue>
                <XRef ID="MONDO:0009262" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE III</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0013" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0014" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2431" />
                <XRef ID="2431" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="79257" DB="Orphanet" />
              <XRef ID="C0268273" DB="MedGen" />
              <XRef ID="MONDO:0009262" DB="MONDO" />
              <XRef Type="MIM" ID="230650" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="247" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="21135" SubmissionDate="2021-05-05" DateLastUpdated="2021-05-10" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="611458.0014_GM1-GANGLIOSIDOSIS, TYPE I" title="GLB1, IVS1DS, 1-BP INS, +3_GM1-GANGLIOSIDOSIS, TYPE I" />
        <ClinVarAccession Accession="SCV000021135" DateUpdated="2021-05-10" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1994-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 sibs affected by the severe infantile form of GM1-gangliosidosis (GM1G1; 230500), Morrone et al. (1994) identified homozygosity for a 1-bp insertion (insT) in the +3 position of intron 1 of the GLB1 gene immediately downstream of the conserved GT splice donor dinucleotide. The insertion resulted in 2 aberrant transcripts, 1 containing a 20-nucleotide insertion derived from the 5-prime end of intron 1 and a second in which sequences encoded by exon 2 were deleted during the splicing process.</Attribute>
              <Citation>
                <ID Source="PubMed">8199591</ID>
              </Citation>
              <XRef DB="OMIM" ID="230500" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Chakraborty et al. (1994) identified heterozygosity for the intron 1 insT mutation in 2 sibs with GM1-gangliosidosis. They were compound heterozygous for another GLB1 mutation that had residual enzyme activity, T82M (611458.0013), yielding a phenotype consistent with the adult form of the disorder (GM1G3; 230650).</Attribute>
              <Citation>
                <ID Source="PubMed">8198123</ID>
              </Citation>
              <XRef DB="OMIM" ID="230650" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <Name>GLB1, IVS1DS, 1-BP INS, +3</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">IVS1DS, 1-BP INS, +3</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="611458.0014" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GM1-GANGLIOSIDOSIS, TYPE I</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3098082" SubmissionDate="2021-05-05" DateLastUpdated="2021-05-10" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="611458.0014_GM1-GANGLIOSIDOSIS, TYPE III" title="GLB1, IVS1DS, 1-BP INS, +3_GM1-GANGLIOSIDOSIS, TYPE III" />
        <ClinVarAccession Accession="SCV001573206" DateUpdated="2021-05-10" DateCreated="2021-05-10" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1994-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 sibs affected by the severe infantile form of GM1-gangliosidosis (GM1G1; 230500), Morrone et al. (1994) identified homozygosity for a 1-bp insertion (insT) in the +3 position of intron 1 of the GLB1 gene immediately downstream of the conserved GT splice donor dinucleotide. The insertion resulted in 2 aberrant transcripts, 1 containing a 20-nucleotide insertion derived from the 5-prime end of intron 1 and a second in which sequences encoded by exon 2 were deleted during the splicing process.</Attribute>
              <Citation>
                <ID Source="PubMed">8199591</ID>
              </Citation>
              <XRef DB="OMIM" ID="230500" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Chakraborty et al. (1994) identified heterozygosity for the intron 1 insT mutation in 2 sibs with GM1-gangliosidosis. They were compound heterozygous for another GLB1 mutation that had residual enzyme activity, T82M (611458.0013), yielding a phenotype consistent with the adult form of the disorder (GM1G3; 230650).</Attribute>
              <Citation>
                <ID Source="PubMed">8198123</ID>
              </Citation>
              <XRef DB="OMIM" ID="230650" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <Name>GLB1, IVS1DS, 1-BP INS, +3</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">IVS1DS, 1-BP INS, +3</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="611458.0014" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">GM1-GANGLIOSIDOSIS, TYPE III</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4023921" SubmissionDate="2022-01-04" DateLastUpdated="2022-01-08" DateCreated="2022-01-08">
        <ClinVarSubmissionID localKey="NM_000404.2:c.75+2dup|OMIM:230500" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002053879" DateUpdated="2022-01-08" DateCreated="2022-01-08" Type="SCV" Version="1" SubmitterName="Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India" OrgID="505991" OrganizationCategory="laboratory" OrgAbbreviation="KMC-MAHE" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.2:c.75+2dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230500" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10900200</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5415322" SubmissionDate="2022-12-21" DateLastUpdated="2022-12-24" DateCreated="2022-12-24">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000404_3_GLB1_c_75_2dupT" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002768710" DateUpdated="2022-12-24" DateCreated="2022-12-24" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-06-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8198123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8199591</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21497194</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as pathogenic. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0106 - This gene is known to be associated with autosomal recessive disease. (N) 0209 - Splice variant (canonical or non-canonical) proven to affect splicing/expression of the transcript with uncertain effect on protein structure (intron 1 of 15). Functional studies have proven this variant results in two new mRNA transcripts; a frameshift which is predicted to undergo nonsense mediated decay (PMID: 8198123), and the inframe skipping of exon 2 (PMID: 8199591). (P) 0251 - Variant is heterozygous. (N) 0304 - Variant is present in gnomAD v2 &lt;0.01 for a recessive condition (58 heterozygotes, 0 homozygotes). (P) 0505 - Abnormal splicing is predicted by in silico tools. (P) 0801 - Strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as pathogenic in multiple patients with GM1 gangliosidosis. Homozygous patients, or those in compound heterozygous with a truncating variant, had severe, infantile onset disease. A patient in compound heterozygous with a missense variant had a milder form of disease (ClinVar, PMID: 8198123, PMID: 8199591, PMID: 21497194). (P) 1208 - Inheritance information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_2485</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.3:c.75+2dupT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0009260" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_38</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1829473" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="1506306|MedGen:C0086652;C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000935642" DateUpdated="2024-02-28" DateCreated="2019-08-14" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8198123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8199591</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29160035</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17576681</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9536098</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8198123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8199591</ID>
          </Citation>
          <Comment>This sequence change falls in intron 1 of the GLB1 gene. It does not directly change the encoded amino acid sequence of the GLB1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs766823411, gnomAD 0.1%). This variant has been observed in individuals with GM1 gangliosidosis (PMID: 8198123, 8199591, 29160035). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 936). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in retention of 20bp of intron1 and introduces a premature termination codon (PMID: 8198123, 8199591). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33138500_33138501insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1741294" SubmissionDate="2018-08-22" DateLastUpdated="2019-03-19" DateCreated="2019-03-19">
        <ClinVarSubmissionID localKey="NM_000404.2: c.75+2_75+3insT" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000889975" DateUpdated="2019-03-19" DateCreated="2019-03-19" Type="SCV" Version="1" SubmitterName="Molecular Diagnostics Laboratory, M Health Fairview: University of Minnesota" OrgID="506641" OrganizationCategory="laboratory" OrgAbbreviation="UMMC-MDL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-08-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8198123</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.2:c.75+2_75+3insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230500" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4433710</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1796087" SubmissionDate="2019-04-24" DateLastUpdated="2019-06-02" DateCreated="2019-06-02">
        <ClinVarSubmissionID localKey="NM_000404.2:c.75+2dupT|MedGen:C0086652" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000919466" DateUpdated="2019-06-02" DateCreated="2019-06-02" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-05-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8198123</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21497194</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8199591</ID>
          </Citation>
          <Comment>Variant summary: GLB1 c.75+2dupT is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Five predict the variant abolishes a 5 prime splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing. The variant allele was found at a frequency of 0.00021 in 271704 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in GLB1 causing GM1 gangliosidosis (0.00021 vs 0.002), allowing no conclusion about variant significance. c.75+2dupT has been reported in the literature in multiple individuals affected with GM1 gangliosidosis. These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in &lt;10% of normal activity. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified it as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.2:c.75+2dupT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5494893</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="958006" SubmissionDate="2023-01-25" DateLastUpdated="2023-02-07" DateCreated="2017-01-09">
        <ClinVarSubmissionID localKey="GDXSV:256872" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000490537" DateUpdated="2023-02-07" DateCreated="2017-01-09" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant results in activation of a cryptic splice donor site and insertion of 20 base pairs of intronic sequence, resulting in a frameshift and protein truncation (Chakraborty et al., 1994; Morrone et al., 1994); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 8199591, 33737400, 21497194, 29352662, 30408610, 25936995, 29160035, 28476546, 31761138, 33942996, 33240792, 33558080, 8198123)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="3" alternateAllele="A" referenceAllele="-" start="33138500" stop="33138501" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:24253</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_161_20230125054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7575434" SubmissionDate="2023-10-19" DateLastUpdated="2023-10-28" DateCreated="2023-10-28">
        <ClinVarSubmissionID localKey="20200124054" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004047015" DateUpdated="2023-10-28" DateCreated="2023-10-28" Type="SCV" Version="1" SubmitterName="Neuberg Centre For Genomic Medicine, NCGM" OrgID="508108" OrganizationCategory="laboratory" OrgAbbreviation="NCGM" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The splice site c.75+2dup variant in the GLB1 gene has been reported in a compound heterozygous state in an individual affected with GM1 gangliosidosis (Myers KA. et al., 2018). Experimental studies have shown that this variant disrupts mRNA splicing (Morrone A. et al., 1994). This variant is reported with the allele frequency (0.02%) in the gnomAD and is novel (not in any individuals) in 1000 genome database. It has been submitted to ClinVar as a Pathogenic variant. This variant affects the invariant GT donor splice site. This nucleotide change in GLB1 is predicted to be conserved across species. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0002344" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0012758" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0002123" />
              </Trait>
              <Comment>Clinical symptoms : Bad obstetric history Family history: couple had 2 girl children both died at the age of 1.5 years, 1st child succumbed due to status epilepticum and 2nd child due to lower respiratory tract infection. Both had global developmental delay, hearing and vision loss, progressive macrocephaly, abdominal distension, recurrent lower respiratory tract infections and seizures from 7th month of life. Investigation- CT Brain was done revealed B/L basal ganglia and parietal lobe calcification, presence of B/L grey fundal glow suspected as CMV infection or macular hypoplasia.</Comment>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.75+2dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13901154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7575434" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002344" MappingRef="HP">
        <MedGen CUI="C1854838" Name="Progressive neurologic deterioration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4023921" TraitType="Disease" MappingType="XRef" MappingValue="230500" MappingRef="OMIM">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="958006" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1741294" TraitType="Disease" MappingType="XRef" MappingValue="230500" MappingRef="OMIM">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3098082" TraitType="Disease" MappingType="Name" MappingValue="GM1-GANGLIOSIDOSIS, TYPE III" MappingRef="Alternate">
        <MedGen CUI="C0268273" Name="GM1 gangliosidosis type 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575434" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002123" MappingRef="HP">
        <MedGen CUI="C4021759" Name="Generalized myoclonic seizure" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1829473" TraitType="Disease" MappingType="XRef" MappingValue="C0085131" MappingRef="MedGen">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1829473" TraitType="Disease" MappingType="XRef" MappingValue="C0086652" MappingRef="MedGen">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1796087" TraitType="Disease" MappingType="Name" MappingValue="Mucopolysaccharidosis, MPS-IV-B" MappingRef="Preferred">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="21135" TraitType="Disease" MappingType="Name" MappingValue="GM1-GANGLIOSIDOSIS, TYPE I" MappingRef="Preferred">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575434" TraitType="Disease" MappingType="XRef" MappingValue="230600" MappingRef="OMIM">
        <MedGen CUI="C0268272" Name="GM1 gangliosidosis type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575434" TraitType="Finding" MappingType="XRef" MappingValue="HP:0012758" MappingRef="HP">
        <MedGen CUI="C4022738" Name="Neurodevelopmental delay" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5415322" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0009260" MappingRef="MONDO">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

